Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of \[68Ga\]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Participants needed: 65
Trial details
Phase: Phase 2Age: 18-79Biological sex: AllType: InterventionalSponsor: Blue Earth DiagnosticsUpdated: Jul 15, 2026Locations: 6
Eligibility criteria

Participants provide informed consent and confirm that they are able and willing... [+9]

Participants administered any radioisotope within 5 physical half-lives prior to... [+14]

Read more
Status: Recruiting

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Participants needed: 71
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Blue Earth DiagnosticsUpdated: Jun 23, 2026Locations: 1
Eligibility criteria

Participants provide informed consent and confirm that they are able and willing... [+10]

Participants administered any radioisotope within 5 physical half-lives prior to... [+11]

Read more
Status: Not yet recruiting

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence

Participants needed: 142
Trial details
Phase: Phase 4Age: 18+Biological sex: MaleType: InterventionalSponsor: Blue Earth DiagnosticsUpdated: Jun 2, 2026Locations: 6
Eligibility criteria

Participants must be males aged ≥18 years at Screening. [+5]

Participants with known metastatic castrate resistant prostate cancer. [+6]

Read more